PathAI and AISight have collaborated to launch AIM-MASH on the AISight Image Management System, providing AI-based support for analyzing MASLD Activity Score component grades and fibrosis staging. With projections of 27 million MASH cases in the US by 2030, this tool aims to increase reproducibility and scalability for pathologists. Through over 20 presentations and publications, AIM-MASH has shown to offer highly sensitive and specific reviews, repeatable assessments, and increased scoring confidence, ultimately improving patient outcomes in pathology.

In today's episode, we cover innovative products and partnerships making waves in various industries. Safety Shot, Inc., listed on NASDAQ as SHOT, is gaining attention for its patented beverage designed to lower blood alcohol content. XpertDox partners with QuickVisit Urgent Care to streamline medical coding processes in rural clinics using AI technology. Resonance Sports Acupuncture, founded by Lauren Mendez, has relocated to a new location in Golden, Colorado, offering high-quality treatments for athletes and active individuals.

In this episode, Brett Vance discusses concerns about COVID-19 vaccine injuries among flight crews, highlighting risks like myocarditis and neurological problems. Alzamend Neuro partners with Massachusetts General Hospital for a Phase II trial of a next-generation treatment for Major Depressive Disorder. Benchmark International releases its 2024 Global Healthcare & Medical Industry Report, providing insights on market trends and opportunities. Therma Bright Inc. is making strides in the global medical devices market, securing investments and FDA approval for key devices. TexasPlans.com offers a guide to help Texas residents navigate the Health Exchange subsidy income chart for maximum savings on health insurance.

Dr. Patrick Porter receives the 'Health & Wellness' award at the 2nd Annual 4BIDDEN Conscious Awards for his BrainTap technology. CheersAI, a mental health support platform created by high school students, is now live. CaRe Clinic joins hyperCORE International to advance clinical research, and Psych Choices welcomes Mallory Mizvitowicz, a Psychiatric Nurse Practitioner. Dermatologist Kyle Owens is named a 2024 Castle Connolly Rising Star, and NEC Bio Therapeutics partners with AGC Biologics to advance personalized cancer vaccine production.

In this episode, we cover groundbreaking collaborations and advancements in the healthcare industry. Alzamend Neuro, Inc. partners with Massachusetts General Hospital for a Phase II trial of AL001, a potential game-changer in bipolar disorder treatment. Citius Pharmaceuticals Inc. merges with TenX Keane Acquisition to form Citius Oncology, Inc., focusing on developing novel targeted oncology therapies. Mental health issues are on the rise, with Alzamend Neuro advancing new treatments for various disorders. HPS/PayMedix acquires TempoPay to enhance healthcare payments, addressing affordability issues. The Anosh Inc. Foundation announces its largest program expansion, focusing on healthcare access, education, mentorship, food security, and senior care. The Citizens Commission on Human Rights hosts an event in honor of Purple Heart Day, emphasizing community support for military members and veterans.

Today's episode covers the growth and potential of regenerative medicine technology, with Regenerative Medicine Technology Group (MSSV) leading the way in innovative treatments for various conditions. Fraternity Mutual receives the 2024 Medical Innovation Award for their advancements in medical data management and AI-driven consultations. Additionally, the dangers of hot pavement in California's Sacramento Valley are highlighted, with tips from Dr. Phong Le on how to protect your feet from thermal burns.

Hyro's survey reveals US patients facing challenges in healthcare journey, with delays in prescription refills and health complications. Patients seek more self-service options and prefer AI assistants over hold times. Providers must implement AI responsibly to meet patient expectations. MMRF's Road to Victories cycling program raises funds for myeloma research, supporting efforts to accelerate a cure. Participants will cycle through California Wine Country, with funds directly supporting research and clinical trials. Visit MMRF website for more information.

In this episode, we highlight the 50th anniversary of Mothers' Milk Bank California and their new program to provide safe access to donor milk. Theriva Biologics is making strides in oncolytic virus therapies to improve survival rates for difficult-to-treat cancers. Additionally, CODE Health launches a new podcast series focused on conscious living and holistic wellness. Lastly, iuvo introduces Secure AI Host for data-intensive industries, and CareWork Inc. celebrates significant revenue growth in the senior living and long-term care sector.

Today's episode covers exciting updates from various healthcare and biotech companies. Zynex Inc CEO Thomas Sandgaard discusses the company's growth and future innovations, including FDA approvals for new devices. Syra Health Corp. secures a contract to train healthcare professionals in Indiana, emphasizing health equity principles. Mainz Biomed applies for FDA breakthrough device designation for a promising colorectal cancer test. Global Vision Technologies achieves TX-RAMP Level 2 Certification for their FAMCare Human Services Software. Acarix expands its US market presence with shares now trading on the OTCQB, highlighting growing demand for their CADScor System. Citius Pharmaceuticals nears a market breakthrough with Mino-Lok and LYMPHIR products, while Oncolytics Biotech Inc. works on a promising treatment for pancreatic cancer.

On today's episode, we dive into the groundbreaking advancements in mental health treatment by MIRA Pharmaceuticals (NASDAQ: MIRA). Their compounds, MIRA-55 and Ketamir-2, show promising results in preclinical trials, offering therapeutic benefits without side effects like increased appetite or paranoia. With a focus on patient care, MIRA aims to improve access and affordability for those suffering from neurological and neuropsychiatric disorders. Stay tuned to learn more about their plans to submit an Investigational New Drug application by year-end.